El Guerche-Séblain Clotilde, Moureau Annick, Schiffler Camille, Dupuy Martin, Pepin Stephanie, Samson Sandrine I, Vanhems Philippe, Schellevis François
Global Vaccine and Epidemiology Department, Sanofi Pasteur, Lyon, France.
Global Clinical Biostatistics Department, Sanofi Pasteur, Marcy l'Étoile, France.
BMC Infect Dis. 2019 Apr 4;19(1):308. doi: 10.1186/s12879-019-3920-8.
Despite World Health Organization recommendations, in many countries young children are not targeted for influenza vaccination. To help inform influenza vaccination policy, we examined the occurrence and burden of influenza in healthy children aged 6 to 35 months using data from a recent phase III placebo-controlled influenza vaccine trial conducted in countries in the Northern and Southern Hemispheres.
This was an analysis of data from participants included in the placebo arm of a phase III clinical trial in healthy children aged 6 to 35 months (EudraCT no. 2013-001231-51). Included children had never been vaccinated for influenza and were observed for one influenza season. Outcome measures included the occurrence of influenza-like illness (ILI), laboratory-confirmed influenza, virus types/subtypes, severe symptoms and complications of confirmed influenza, and healthcare use associated with confirmed influenza.
Data from 2210 participants were analysed. ILI was reported for 811 participants (36.7%). Of these, 255 participants (31.4%) had 263 virologically confirmed episodes of influenza. The overall influenza attack rate was 11.5%. The most common influenza virus detected was A(H3N2) (40.7%), followed by B/Yamagata (23.6%), A(H1N1) (18.6%), and B/Victoria (8.0%). Grade 3 fever was reported in 24.3% of confirmed episodes, acute lower respiratory infection in 8.7%, acute otitis media in 6.1%, and pneumonia in 1.9%. In most influenza episodes (93.2%), antipyretics, analgesics, or non-steroidal anti-inflammatory drugs were taken. Antibiotics were prescribed for 41.4% of influenza episodes. More than half of the influenza episodes (57.0%) resulted in outpatient visits. Influenza resulted in overnight hospitalisation in 1.1% of episodes.
Influenza is associated with a significant burden of disease in healthy children. This analysis also revealed that antibiotics continue to be frequently used for young children with influenza.
EudraCT no. 2013-001231-51 .
尽管世界卫生组织有相关建议,但在许多国家,幼儿并非流感疫苗接种的目标人群。为了给流感疫苗接种政策提供参考依据,我们利用近期在北半球和南半球国家开展的一项III期安慰剂对照流感疫苗试验的数据,研究了6至35个月健康儿童流感的发病情况及负担。
这是一项对6至35个月健康儿童III期临床试验安慰剂组参与者数据的分析(欧洲临床试验注册号:2013-001231-51)。纳入的儿童从未接种过流感疫苗,且观察了一个流感季节。观察指标包括流感样疾病(ILI)的发生情况、实验室确诊的流感、病毒类型/亚型、确诊流感的严重症状和并发症,以及与确诊流感相关的医疗服务使用情况。
分析了2210名参与者的数据。811名参与者(36.7%)报告了流感样疾病。其中,255名参与者(31.4%)有263次病毒学确诊的流感发作。总体流感发病率为11.5%。检测到的最常见流感病毒是A(H3N2)(40.7%),其次是B/山形株(23.6%)、A(H1N1)(18.6%)和B/维多利亚株(8.0%)。确诊发作中24.3%报告有3级发热,8.7%有急性下呼吸道感染,6.1%有急性中耳炎,1.9%有肺炎。在大多数流感发作(93.2%)中,服用了退烧药、镇痛药或非甾体抗炎药。41.4%的流感发作开具了抗生素处方。超过一半的流感发作(57.0%)导致门诊就诊。1.1%的发作导致住院过夜。
流感给健康儿童带来了重大疾病负担。该分析还显示,抗生素在患流感的幼儿中仍被频繁使用。
欧洲临床试验注册号:2013-001231-51 。